• Timing of Immunotherapy in Melanoma

  NCT07696715

  RecruitingInterventionalNot ApplicableUpdated Aug 13, 2026
• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

  NCT07155317

  RecruitingInterventionalPhase 2Updated Nov 12, 2025
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

  NCT06594991

  RecruitingInterventionalPhase 2Updated May 14, 2026
• Immunotherapy Study for Patients With Stage IV Melanoma

  NCT02054520

  TerminatedInterventionalPhase 2Updated Apr 18, 2023
• The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

  NCT07338981

  Not yet recruitingInterventionalPhase 3Updated Jan 14, 2026
• IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

  NCT01409174

  TerminatedInterventionalPhase 1Updated May 31, 2017

ClinicalTrials.gov ID

NCT07574047

Lead Sponsor

Swiss Cancer InstituteOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

108Estimated

Last Update Posted

Jul 31, 2026Actual

Start Date

Sep 2026Estimated

Primary Completion Date

Jun 2030Estimated

Completion Date

Jun 2032Estimated

Official Title

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.

Brief Summary

Melanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime administration of ICIs may enhance therapeutic effectiveness, potentially due to circadian modulation of immune function. A pronounced survival benefit has been observed particularly among female patients receiving earlier infusions. This trial prospectively evaluates whether aligning ICI administration with circadian immune activity can improve outcomes in melanoma and support the development of sex-specific optimization of immunotherapy.

Detailed Description

The introduction of ICIs a decade ago revolutionized the treatment of various malignancies, particularly melanoma. Yet treatment responses are heterogenous and depend on patient characteristics such as sex and age, and tumor characteristics. The relationship between sex and ICI response in melanoma is complex and may be influenced by various factors, including the type of ICI, tumor mutation burden, presence of infiltrating immune cells, microbiome, and concomitant medications affect the immune system's ability to mount antitumor responses. While some retrospective data indicate poorer outcomes for female patients, in other real-world reports female sex is associated with better outcomes. Prospective, sex-stratified clinical studies are necessary to provide a definitive answer and to integrate sex as a critical variable in personalizing melanoma treatment strategies. Temporal variations in antibody responses and anticancer immunity after vaccination have been reported in both humans and mice. Circadian rhythms also remain an important regulator of immune cell activities. The optimal time for inducing adaptive immune responses consistently appears to be situated around or just before behavioral activity; for nocturnal mice this optimal window appears to be the afternoon, while in diurnal humans this may be the early morning. However, the optimal time of day for ICI administration is currently unknown. A retrospective single-center analysis of advanced melanoma patients showed that receiving less than 20% of the ICI infusions after 16h30 was associated with enhanced overall survival. In subgroup analyses, female patients had a significantly longer OS when less than 20% of the treatment was administered after 16h30.

Optimizing the timing of ICI therapy to target the immune system at the time of its highest sensitivity could significantly improve patient outcomes, particularly for female patients, without exposing patients to additional drugs and generating additional toxicity and costs. Given the limitations of retrospective analyses, a prospective randomized trial is essential to obtain results that could potentially change clinical practice.

• Melanoma
• Advanced Melanoma

• Immune Checkpoint Inhibitors

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Written informed consent according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures.
• Histologically confirmed unresectable cutaneous stage III or stage IV melanoma. Note: Participants with central nervous system (CNS) metastases are eligible.
• Participants with a previously treated other malignancy are eligible, if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low.
• Measurable or evaluable disease.
• Age ≥ 18 years.
• Patients deemed suitable for ICI therapy based on the local investigator's clinical assessment.
• ECOG performance status 0-2.
• Women of childbearing potential must use effective contraception , not be pregnant or lactating and agree not to become pregnant during trial treatment and until 5 months after the last dose of trial treatment. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.
• Men agree not to donate sperm or to father a child during trial treatment and until 5 months after the last dose of trial treatment.

Exclusion Criteria:

• Prior treatment with any systemic anti-cancer therapy; with the exception of prior adjuvant anti-PD-1 or BRAF/MEK inhibitor therapy if the time from last dose to recurrence is more than 6 months.
• Recent treatment (within 28 days prior to first dose) with any experimental drug.
• Known history of allogeneic organ transplant.
• Uveal or mucosal melanoma.
• Receipt of live attenuated vaccine within 28 days prior to first dose.
• Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.
• Known hypersensitivity to trial drug(s) or to any component of the trial drug(s).
• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect participant compliance or place the participant at high risk from treatment-related complications.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Swiss Cancer InstituteOTHER

cristina.mangas@eoc.ch+41 91 811 94 11

berna.oezdemir@insel.ch+41 31 632 81 95